Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 64

1.

The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development.

Morrow Guthrie K, Vargas S, Shaw JG, Rosen RK, van den Berg JJ, Kiser PF, Buckheit K, Bregman D, Thompson L, Jensen K, Johnson T, Buckheit RW.

PLoS One. 2015 Dec 22;10(12):e0145642. doi: 10.1371/journal.pone.0145642. eCollection 2015.

2.

A Human Immunodeficiency Virus Controller With a Large Population of CD4(+)CD8(+) Double-Positive T Cells.

Durand CM, Buckheit RW 3rd, Salgado M, Pohlmeyer CW, Walker-Sperling VE, Hegarty RW, Ambinder RF, Blankson JN.

Open Forum Infect Dis. 2015 Mar 20;2(2):ofv039. doi: 10.1093/ofid/ofv039. eCollection 2015 Apr.

3.

The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.

Ham AS, Nugent ST, Peters JJ, Katz DF, Shelter CM, Dezzutti CS, Boczar AD, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2015 Aug;120:153-64. doi: 10.1016/j.antiviral.2015.06.010. Epub 2015 Jun 17.

4.

Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors.

Ham AS, Buckheit RW Jr.

Ther Deliv. 2015 Feb;6(2):217-29. doi: 10.4155/tde.14.110. Review.

5.

Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.

Moulaei T, Alexandre KB, Shenoy SR, Meyerson JR, Krumpe LR, Constantine B, Wilson J, Buckheit RW Jr, McMahon JB, Subramaniam S, Wlodawer A, O'Keefe BR.

Retrovirology. 2015 Jan 23;12:6. doi: 10.1186/s12977-014-0127-3.

6.

Anti-HSV activity of serpin antithrombin III.

Quenelle DC, Hartman TL, Buckheit RW, Prichard MN, Lynn RG.

Int Trends Immun. 2014 Apr;2(2):87-92.

7.

Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.

Walker-Sperling VE, Buckheit RW 3rd, Blankson JN.

J Virol. 2014 Sep 1;88(17):9789-98. doi: 10.1128/JVI.00860-14. Epub 2014 Jun 18.

8.

Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual.

Buckheit RW 3rd, Sexauer SB, Sedaghat AR, Wilke CO, Laeyendecker O, Basseth CR, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):511-3. doi: 10.1089/AID.2014.0054. No abstract available.

9.

Synthesis and Biological Evaluation of 5'-O-Dicarboxylic Fatty Acyl Monoester Derivatives of Anti-HIV Nucleoside Reverse Transcriptase Inhibitors.

Pemmaraju B, Agarwal HK, Oh D, Buckheit KW, Buckheit RW Jr, Tiwari R, Parang K.

Tetrahedron Lett. 2014 Mar 19;55(12):1983-1986.

10.

HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon.

Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, Pardoll D, Cox AL.

PLoS Pathog. 2014 May 1;10(5):e1004082. doi: 10.1371/journal.ppat.1004082. eCollection 2014 May.

11.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

12.

CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.

Pohlmeyer CW, Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Dec 12;10:152. doi: 10.1186/1742-4690-10-152.

13.

"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.

van den Berg JJ, Rosen RK, Bregman DE, Thompson LA, Jensen KM, Kiser PF, Katz DF, Buckheit K, Buckheit RW Jr, Morrow KM.

AIDS Behav. 2014 May;18(5):862-70. doi: 10.1007/s10461-013-0652-4.

14.

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties.

Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC.

Retrovirology. 2013 Oct 24;10:113. doi: 10.1186/1742-4690-10-113.

15.

Evolution of an attenuated HIV-1 isolate in an elite suppressor.

Salgado M, Gandhi S, Buckheit RW, Berkenblit GV, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):284-8. doi: 10.1089/AID.2013.0229. Epub 2013 Nov 13.

16.

In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410.

Ham AS, Lustig W, Yang L, Boczar A, Buckheit KW, Buckheit RW Jr.

PLoS One. 2013 Sep 18;8(9):e75306. doi: 10.1371/journal.pone.0075306. eCollection 2013.

17.

Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells.

Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Jul 1;10:68. doi: 10.1186/1742-4690-10-68.

18.

Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.

Buckheit RW 3rd, Salgado M, Silciano RF, Blankson JN.

J Virol. 2012 Dec;86(24):13679-88. doi: 10.1128/JVI.02439-12. Epub 2012 Oct 10.

19.

Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.

Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2012 Nov;96(2):221-5. doi: 10.1016/j.antiviral.2012.08.004. Epub 2012 Aug 23.

20.

Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1.

Buckheit KW, Buckheit RW Jr.

Mol Biol Int. 2012;2012:781305. doi: 10.1155/2012/781305. Epub 2012 Jul 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk